Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06550076 · ClinicalTrials.gov registry record · Phase 3
A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis
A Phase 3 study of Plaque Psoriasis, sponsored by Takeda.
- Active
- Registry status
- Phase 3
- Development phase
- 1,950
- Enrollment target
- 20
- Study locations
NCT06550076 is a Phase 3 study of Plaque Psoriasis that is active but no longer recruiting, run by Takeda. The registered enrollment target is 1,950 participants, above the 373-participant average among 45 other Plaque Psoriasis trials with a reported enrollment target (423% higher). The trial reports 20 study locations across 4 states.
The verdict
NCT06550076, a Phase 3 study of Plaque Psoriasis, is active but no longer recruiting, sponsored by Takeda.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,950 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main aim of this study is to check the side effects of TAK-279 and how well it is tolerated in participants with moderate-to-severe plaque psoriasis. All participants will be assigned to study treatments of TAK-279 and will be treated with TAK-279 if the participants meet the study rules. Participants will be in the study for up to 217 weeks, including up to 35 days for the screening period, 52 weeks (Part A) up to 156 additional weeks (Part B) study treatment and 4 weeks follow up period. During the study, participants will visit their study clinic multiple times.
Conditions Studied
Interventions
- DRUG TAK-279
Study Locations (20)
California
- Zenith Research, Inc. - Beverly Hills
- First OC Dermatology Research Inc. - Fountain Valley
- Center for Dermatology Clinical Research - Fremont
- Long Beach Research Institute - Long Beach
- Metropolis Dermatology Downtown LA - Probity - PPDS - Los Angeles
- UCLA University of California Los Angeles - Los Angeles
- Northridge Clinical Trials - Northridge
- UC Davis Dermatology Clinic - Sacramento
- TCR Medical Corporation - San Diego
- University Clinical Trials - San Diego
- Dermatology Institute and Skin Care Center - Santa Monica
- UNISON Clinical Trials (Shahram Jacobs md inc.) - Sherman Oaks
Alabama
- Total Dermatology - Birmingham
- University of Alabama Hospital - Whitaker Clinic - - Birmingham
- Cahaba Dermatology Skin Health Center - Hoover
Arizona
- Medical Dermatology Specialists - Phoenix
- Saguaro Dermatology Associates, LLC - Probity - PPDS - Phoenix
- Noble Clinical Research - Tucson
Arkansas
- Johnson Dermatology Clinic - Fort Smith
- Burke Pharmaceutical Research - Hot Springs
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,950 participants |
| Start Date | 2024-09-04 |
| Est. Completion | 2026-05-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06550076
The ClinicalTrials.gov registry entry for NCT06550076 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 1,950 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 373-participant average among 45 other Plaque Psoriasis trials with a reported enrollment target (423% higher). The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Plaque Psoriasis appearing as the primary indexed condition, and to 1 intervention - of which TAK-279 is the first listed.
NCT06550076 reports 20 study locations spanning 4 distinct geographic areas - top geographies include California, Alabama, Arizona.
Frequently Asked Questions
What is clinical trial NCT06550076 about?
NCT06550076 is a clinical study titled "A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis". The main aim of this study is to check the side effects of TAK-279 and how well it is tolerated in participants with moderate-to-severe plaque psoriasis. All participants will be assigned to study treatments of TAK-279 and will be treated with TAK-279 if the participants meet the study rules. Part...
What is the current status of trial NCT06550076?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,950 participants. The study started on 2024-09-04. Estimated completion is 2026-05-07.
What conditions does trial NCT06550076 study?
This clinical trial studies the following conditions: Plaque Psoriasis.
What interventions are being tested in trial NCT06550076?
The interventions under investigation include: TAK-279 (DRUG).
Who is sponsoring clinical trial NCT06550076?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06550076 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Plaque Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
RECRUITING · Phase 3
-
A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
RECRUITING · Phase 3
-
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
ACTIVE NOT RECRUITING · Phase 3
-
A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet)
ACTIVE NOT RECRUITING · Phase 3
-
Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.